Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Respiratory Syncytial Virus Antigens and Antibodies

Applications in Therapeutic Antibody, Vaccine, and Immunodiagnostic Assay Development

Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness in children globally. Sino Biological has developed a comprehensive collection of RSV-related reagents for viral research (18 antigens, 12 antibodies, 3 ELISA Kits, 76 cDNAs, 10 lysates, and peptide pool) that covers RSV A and B from over 5 strains, supporting therapeutic antibody, vaccine, and immunodiagnostic assay development.

Click for more about RSV antigens and antibodies.

Featured Product: Validated RSV Pre-F Trimer Protein

The Fusion (F) protein presents as a trimer on the surface of the RSV virion and plays a key role in virus invasion. Obtaining stable pre-fusion (Pre-F) proteins is crucial for RSV vaccine development. Sino Biological has developed a stable pre-fusion protein with a 90% trimerization ratio validated by SEC-MALS, which can support the development of RSV vaccines.

Click for more about RSV pre-fusion reagents.

More about Virus Antigens and Antibodies:

Herpes Virus Antigens and Antibodies

Influenza Vaccine Development and Production Solutions

Comprehensive Toolkits for SARS-CoV-2 Variants Research

Viral Antigen Bank

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
VAT nummer: DE323950120


Sino Biological Europe GmbH

Sänd till en kollega